170 related articles for article (PubMed ID: 10435083)
1. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans.
Palù G; Cavaggioni A; Calvi P; Franchin E; Pizzato M; Boschetto R; Parolin C; Chilosi M; Ferrini S; Zanusso A; Colombo F
Gene Ther; 1999 Mar; 6(3):330-7. PubMed ID: 10435083
[TBL] [Abstract][Full Text] [Related]
2. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
[TBL] [Abstract][Full Text] [Related]
3. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results.
Colombo F; Barzon L; Franchin E; Pacenti M; Pinna V; Danieli D; Zanusso M; Palù G
Cancer Gene Ther; 2005 Oct; 12(10):835-48. PubMed ID: 15891772
[TBL] [Abstract][Full Text] [Related]
4. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy.
Izquierdo M; Cortés M; de Felipe P; Martín V; Díez-Guerra J; Talavera A; Perez-Higueras A
Gene Ther; 1995 Jan; 2(1):66-9. PubMed ID: 7712334
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 gene therapy in a patient with glioblastoma.
Sobol RE; Fakhrai H; Shawler D; Gjerset R; Dorigo O; Carson C; Khaleghi T; Koziol J; Shiftan TA; Royston I
Gene Ther; 1995 Mar; 2(2):164-7. PubMed ID: 7719933
[TBL] [Abstract][Full Text] [Related]
6. HSV-TK/IL-2 gene therapy for glioblastoma multiforme.
Barzon L; Pacenti M; Franchin E; Colombo F; Palù G
Methods Mol Biol; 2009; 542():529-49. PubMed ID: 19565921
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.
Gupta V; Wang W; Sosnowski BA; Hofman FM; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E26. PubMed ID: 16709032
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration.
Niranjan A; Moriuchi S; Lunsford LD; Kondziolka D; Flickinger JC; Fellows W; Rajendiran S; Tamura M; Cohen JB; Glorioso JC
Mol Ther; 2000 Aug; 2(2):114-20. PubMed ID: 10947938
[TBL] [Abstract][Full Text] [Related]
9. Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma.
Floeth FW; Shand N; Bojar H; Prisack HB; Felsberg J; Neuen-Jacob E; Aulich A; Burger KJ; Bock WJ; Weber F
Cancer Gene Ther; 2001 Nov; 8(11):843-51. PubMed ID: 11773974
[TBL] [Abstract][Full Text] [Related]
10. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
Kuriyama N; Kuriyama H; Julin CM; Lamborn KR; Israel MA
Cancer Res; 2001 Mar; 61(5):1805-9. PubMed ID: 11280727
[TBL] [Abstract][Full Text] [Related]
11. Glia/ischemia tissue dual specific gene expression vector for glioblastoma gene therapy.
Kim HA; Park JH; Cho SH; Lee J; Lee M
J Control Release; 2011 Nov; 152 Suppl 1():e146-8. PubMed ID: 22195812
[No Abstract] [Full Text] [Related]
12. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU.
Maleniak TC; Darling JL; Lowenstein PR; Castro MG
Cancer Gene Ther; 2001 Aug; 8(8):589-98. PubMed ID: 11571537
[TBL] [Abstract][Full Text] [Related]
13. [The biosafety of the HSV-TK/GCV gene therapy in five cases of recurrent glioblastoma multiforme].
Adachi N; Könü DL; Frei K; Yonekawa Y
No Shinkei Geka; 2000 Nov; 28(11):965-74. PubMed ID: 11127592
[TBL] [Abstract][Full Text] [Related]
14. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.
Moriuchi S; Krisky DM; Marconi PC; Tamura M; Shimizu K; Yoshimine T; Cohen JB; Glorioso JC
Gene Ther; 2000 Sep; 7(17):1483-90. PubMed ID: 11001368
[TBL] [Abstract][Full Text] [Related]
15. Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
Marconi P; Tamura M; Moriuchi S; Krisky DM; Niranjan A; Goins WF; Cohen JB; Glorioso JC
Mol Ther; 2000 Jan; 1(1):71-81. PubMed ID: 10933914
[TBL] [Abstract][Full Text] [Related]
16. Novartis reclaims tk technology.
Johnson E
Nat Biotechnol; 1997 Mar; 15(3):211. PubMed ID: 9062913
[No Abstract] [Full Text] [Related]
17. Total vascular exclusion of the liver enhances the efficacy of retroviral-mediated associated thymidine kinase and interleukin-2 genes transfer against multiple hepatic tumors in rats.
Alves A; Charre L; Panis Y; Cardoso J; Fabre M; Brisson E; Houssin D; Soubrane O; Klatzmann D
Surgery; 2003 Jun; 133(6):669-77. PubMed ID: 12796736
[TBL] [Abstract][Full Text] [Related]
18. Liposome-mediated suicide gene therapy in humans.
Reszka RC; Jacobs A; Voges J
Methods Enzymol; 2005; 391():200-8. PubMed ID: 15721383
[TBL] [Abstract][Full Text] [Related]
19. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma.
Miletic H; Fischer YH; Giroglou T; Rueger MA; Winkeler A; Li H; Himmelreich U; Stenzel W; Jacobs AH; von Laer D
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6761-8. PubMed ID: 18006778
[TBL] [Abstract][Full Text] [Related]
20. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.
Mukherjee S; Haenel T; Himbeck R; Scott B; Ramshaw I; Lake RA; Harnett G; Phillips P; Morey S; Smith D; Davidson JA; Musk AW; Robinson B
Cancer Gene Ther; 2000 May; 7(5):663-70. PubMed ID: 10830713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
